Opthea Future Growth

Future criteria checks 5/6

Opthea is forecast to grow earnings and revenue by 61.9% and 51.7% per annum respectively while EPS is expected to grow by 67.8% per annum.

Key information

61.9%

Earnings growth rate

67.8%

EPS growth rate

Biotechs earnings growth	42.7%
Revenue growth rate	51.7%
Future return on equity	n/a
Analyst coverage	Good
Last updated	04 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:UKJ - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2027	225	55	-67	-44	8
6/30/2026	72	-104	-79	-29	9
6/30/2025	6	-173	-167	-171	9
6/30/2024	0	-220	-161	-161	N/A
3/31/2024	0	-191	-141	-141	N/A
12/31/2023	0	-162	-121	-121	N/A
9/30/2023	0	-152	-121	-121	N/A
6/30/2023	0	-143	-121	-121	N/A
3/31/2023	0	-137	-116	-116	N/A
12/31/2022	0	-132	-112	-112	N/A
9/30/2022	0	-113	-92	-92	N/A
6/30/2022	0	-93	-71	-71	N/A
3/31/2022	0	-75	-64	-64	N/A
12/31/2021	0	-57	-56	-56	N/A
9/30/2021	0	-51	-51	-51	N/A
6/30/2021	0	-45	-46	-46	N/A
3/31/2021	0	-39	-36	-36	N/A
12/31/2020	0	-31	-27	-27	N/A
9/30/2020	0	-21	-16	-16	N/A
6/30/2020	0	-11	-6	-6	N/A
3/31/2020	0	-10	-7	-7	N/A
12/31/2019	0	-12	-10	-10	N/A
9/30/2019	0	-13	-13	-13	N/A
6/30/2019	0	-15	-17	-17	N/A
3/31/2019	0	-13	-14	-14	N/A
12/31/2018	0	-12	-11	-11	N/A
9/30/2018	0	-12	-13	-13	N/A
6/30/2018	0	-13	-15	-15	N/A
3/31/2018	0	-12	N/A	-13	N/A
12/31/2017	0	-12	N/A	-11	N/A
9/30/2017	0	-8	N/A	-8	N/A
6/30/2017	0	-5	N/A	-5	N/A
3/31/2017	0	-5	N/A	-4	N/A
12/31/2016	0	-5	N/A	-3	N/A
9/30/2016	0	-5	N/A	-3	N/A
6/30/2016	0	-5	N/A	-3	N/A
3/31/2016	0	-4	N/A	-2	N/A
12/31/2015	0	-3	N/A	-1	N/A
9/30/2015	0	-3	N/A	-2	N/A
6/30/2015	0	-4	N/A	-4	N/A
3/31/2015	1	-4	N/A	-4	N/A
12/31/2014	1	-4	N/A	-4	N/A
9/30/2014	1	-4	N/A	-4	N/A
6/30/2014	1	-4	N/A	-4	N/A
3/31/2014	1	-3	N/A	-4	N/A
12/31/2013	1	-2	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: UKJ is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: UKJ is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: UKJ is expected to become profitable in the next 3 years.

Revenue vs Market: UKJ's revenue (51.7% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: UKJ's revenue (51.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if UKJ's Return on Equity is forecast to be high in 3 years time

Opthea Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Forecast to breakeven in 2027

No longer forecast to breakeven

Forecast to breakeven in 2027

Forecast to breakeven in 2026

Recent updates

Opthea Limited Announces Board Changes

Opthea Limited, Annual General Meeting, Nov 15, 2024

Opthea Limited Appoint Executives

Forecast to breakeven in 2027

Opthea Limited Announces Executive Changes

New minor risk - Profitability

Full year 2024 earnings released: US$0.34 loss per share (vs US$0.32 loss in FY 2023)

No longer forecast to breakeven

New minor risk - Profitability

Opthea Limited Announces Board Appointments

Opthea Limited has completed a Follow-on Equity Offering in the amount of AUD 227.314307 million.

Forecast to breakeven in 2027

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

New major risk - Financial position

Less than half of directors are independent

Opthea Limited Announces Board Changes

Forecast to breakeven in 2026

Founder recently sold €1.3m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: US$0.32 loss per share (vs US$0.26 loss in FY 2022)

Full year 2023 earnings released: US$0.32 loss per share (vs US$0.26 loss in FY 2022)

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

High number of new directors

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: US$0.26 loss per share (vs US$0.14 loss in FY 2021)

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

High number of new directors

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

High number of new directors

Opthea Limited Announces Board Appointments

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.043 loss in FY 2020)

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

High number of new directors

Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

Opthea Limited Treats First Patient in Phase 3 Trials of OPT-302

Opthea Limited Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.03 loss in 1H 2020)

New 90-day low: €1.03

New 90-day low: €1.19

New 90-day low: €1.26

Opthea Limited' ADR Deleted from Other OTC

Opthea Limited Appoints Dr. Jeremy Levin as Director

Geoffrey Kempler Retires as A Director of Opthea Limited

New 90-day high: €1.74

Opthea Limited Announces Board Changes

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

New 90-day high - €1.66

Opthea Limited(ASX:OPT) dropped from S&P/ASX Emerging Companies Index

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies